Zevra Therapeutics CMO Steps Down Amid Key Regulatory Milestones — Zevra Therapeutics, Inc.

Event summary

Zevra Therapeutics' CMO Adrian Quartel to step down July 3, 2026, for personal reasons.
Quartel will consult through December 31, 2026, to ensure smooth transition.
Company on track for multiple regulatory milestones, including arimoclomol MAA review by EMA.
Phase 3 trial of celiprolol for VEDS ongoing; FDA discussions planned for H2 2026.

The big picture

Zevra's CMO transition comes as the company navigates critical regulatory milestones, including a pending EMA decision on arimoclomol and ongoing Phase 3 trials. The departure highlights the challenge of maintaining leadership stability during high-stakes drug development phases, particularly in the competitive rare disease space. The company's ability to sustain momentum without its long-standing medical leader will be a key test of its operational resilience.

What we're watching

Leadership Continuity: How Zevra's ability to attract a strong CMO successor will impact its regulatory and clinical execution.
Regulatory Momentum: Whether the EMA's review of arimoclomol for NPC will lead to approval and expand Zevra's commercial footprint.
Pipeline Progress: The pace at which Zevra advances its celiprolol program for VEDS, particularly following FDA discussions in H2 2026.